ReviewDrug safety2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Review in Drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Thoracic cancer · 2025Pooled it
- Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making.Journal of gastrointestinal cancer · 2026Review
- Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- From biology to the clinic: research evidence and therapeutic advances of TROP2-targeted antibody-drug conjugates in small cell lung cancer.Translational lung cancer research · 2026Review
- Management of toxicities from antibody - drug conjugates in breast cancer.Frontiers in oncology · 2026Review
- Real-World Safety of Trastuzumab Deruxtecan in Patients with HER2-Positive and HER2-Low Metastatic Breast Cancer in Saudi Arabia: A Retrospective Cohort Study.International journal of general medicine · 2026Article
- Dose rounding of trastuzumab deruxtecan in chinese patients: cost savings and safety outcomes in real-world study.Frontiers in oncology · 2026Article
- Antibody-Drug Conjugates in Breast Cancer: Therapeutic-Window Engineering, Tumor Heterogeneity, and Immunotherapy Combinations.Drug design, development and therapy · 2026Review
- Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies.The oncologist · 2025Article
- Trastuzumab deruxtecan in the treatment of HER2-positive gastric cancer: a comprehensive review.Future oncology (London, England) · 2025Review
- Disproportionality Analysis of Pulmonary Adverse Events Associated with Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report Database.Clinical drug investigation · 2025Observational
- Trastuzumab-Deruxtecan for the Treatment of Metastatic Breast Cancer Patients: Data from Real World Studies.Cancers · 2025Review
- Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center.Current oncology (Toronto, Ont.) · 2025Article
- Management of trastuzumab deruxtecan-related adverse events in breast cancer: Italian expert panel recommendations.Future oncology (London, England) · 2025Article
- Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers.Cancers · 2025Review
- Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non-Small Cell Lung Cancer: A Case Report.Journal of immunotherapy and precision oncology · 2025Article
- Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.Future oncology (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 12 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trastuzumab deruxtecan (T-DXd)-an antibody-drug conjugate targeting the human epidermal growth factor receptor 2 (HER2)-improved outcomes of patients with HER2-positive and HER2-low metastatic breast cancer. Guidance on monitoring and managing T-DXd-related adverse events (AEs) is an emerging unmet need as translating clinical trial experience into real-world practice may be difficult due to practical and cultural considerations and differences in health care infrastructure. Thus, 13 experts including oncologists, pulmonologists and a radiologist from the Asia-Pacific region gathered to provide recommendations for T-DXd-related AE monitoring and management by using the latest evidence from the DESTINY-Breast trials, our own clinical trial experience and loco-regional health care considerations. While subgroup analysis of Asian (excluding Japanese) versus overall population in the DESTINY-Breast03 uncovered no major differences in the AE profile, we concluded that proactive monitoring and management are essential in maximising the benefits with T-DXd. As interstitial lung disease (ILD)/pneumonitis is a serious AE, patients should undergo regular computed tomography scans, but the frequency may have to account for the median time of ILD/pneumonitis onset and access. Trastuzumab deruxtecan appears to be a highly emetic regimen, and prophylaxis with serotonin receptor antagonists and dexamethasone (with or without neurokinin-1 receptor antagonist) should be considered. Health care professionals should be vigilant for treatable causes of fatigue, and patients should be encouraged to use support groups and practice low-intensity exercises. To increase treatment acceptance, patients should be made aware of alopecia risk prior to starting T-DXd. Detailed monitoring and management recommendations for T-DXd-related AEs are discussed further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.